AVR — Anteris Technologies Global Corp. stock price, charts and financials

Latest market price

8.28

+0.00%

Overview Short InterestFilings

AVRQT62Anteris Technologies Global Corp.·NASDAQ

Overview Short InterestFilings

8.28+0.00%

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

CLPT-16.25%$12.88 CERS+1.86%$2.19 PACB+1.41%$1.44 DCTH+0.77%$13.14 NPCE+4.74%$14.14 OFIX-0.49%$12.20 VREX+3.78%$12.37 KIDS+0.05%$20.88

Snapshot

Index	-	P/E	-	EPS (ttm)	-3.25	Insider Own	48.77%	Shs Outstand	36.79M	Perf Week	1.35%

Market Cap	304.61M	Forward P/E	-	EPS next Y	-0.98	Insider Trans	-9.70%	Shs Float	25.14M	Perf Month	-21.67%

Enterprise Value	24.61M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	32.10%	Perf Quarter	35.07%

Income	-84.00M	P/S	76.15	EPS this Y	66.79%	Inst Trans	-	Short Ratio	6.83	Perf Half Y	34.63%

Sales	4.00M	P/B	1.10	EPS next Y	9.36%	ROA	-32.34%	Short Interest	8.07M	Perf YTD	65.93%

Book/sh	7.56	P/C	1.08	EPS next 5Y	-	ROE	-124.39%	52W High	11.06 -25.14%	Perf Year	169.71%

Cash/sh	7.69	P/FCF	-	EPS past 3/5Y	-	ROIC	-34.04%	52W Low	3.09 167.96%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-12.64% -16.74%	Gross Margin	28.25%	Volatility	5.48% 5.81%	Perf 5Y	-

Dividend TTM	-	EV/Sales	6.15	EPS Y/Y TTM	13.79%	Oper. Margin	-5192.92%	ATR (14)	0.52	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	20.93	Sales Y/Y TTM	33.33%	Profit Margin	-5148.78%	RSI (14)	44.44	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	20.93	EPS Q/Q	54.10%	SMA20	-3.17%	Beta	1.53	Target Price	18.00

Payout	0.00%	Debt/Eq	0.02	Sales Q/Q	-100.00%	SMA50	-9.50%	Rel Volume	1.01	Prev Close	8.28

Employees	174	LT Debt/Eq	0.02	Earnings	Aug 14	SMA200	29.63%	Avg Volume	1.26M	Price	8.28

IPO Date	Dec 13, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3.39% -35.57%	Net Debt/EBITDA	3.01	Volume	1,272,653	Change	0.00%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-15-26	Reiterated	Barclays	Overweight	$18
Jan-23-26	Reiterated	Lake Street		$20 → $15
Jan-07-25	Initiated	Cantor Fitzgerald	Overweight	$9.00

Latest News

Jul-17-26

Jul-17-2608:05AM

12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga

Jul-13-26

Jul-13-2608:03AM

Porch Group, Micron And Other Big Stocks Moving Lower In Monday’s Pre-Market SessionBenzinga

Company

Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020
Total Revenue	4	2	3	3	3	6	5
Cost of Goods Sold Incl. D&A	0	2	1	2	3	4	2
Gross Profit	0	0	1	1	0	2	3
Selling, General and Administrative Excl. Other	0	24	0	17	15	9	3
Research and Development	59	69	51	31	18	10	4
Other Operating Expense	27	1	29	1	-2	0	10
Operating Income	-86	-94	-78	-48	-31	-17	-13
Interest Expense	0	0	0	0	1	1	0
Unusual Expense	—	—	—	—	—	—	—
Non-Operating Income (Expense)	2	0	2	1	1	1	2
Net Income Before Taxes	-84	-94	-76	-47	-31	-17	-12
Income Taxes	0	0	0	0	0	0	0
Consolidated Net Income	-84	-94	-76	-46	-31	-17	-12
Net Income From Continuing Operations	-84	-94	-76	-47	-31	-17	-12
Net Income	-84	-94	-76	-46	-31	-17	-12
EPS (Recurring)	-3.25	-4.00	-3.77	-1.28	-0.85	-0.48	-0.33
EPS (Basic, Before Extraordinaries)	-3.25	-4.00	-3.77	-1.28	-0.85	-0.48	-0.33
EPS (Diluted)	-3.25	-4.00	-3.77	-1.28	-0.85	-0.48	-0.33
EBITDA	-84	-92	-74	-46	-29	-15	-14
Other After Tax Adjustments	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—
Price To Sales Ratio	49.68	59.88	37.20	—	—	—	—
Gross Margin	0.00	0.00	33.33	33.33	0.00	33.33	60.00
Operating Margin	-2,150.00	-4,700.00	-2,600.00	-1,600.00	-1,033.33	-283.33	-260.00
Net Margin	-2,100.00	-4,700.00	-2,533.33	-1,533.33	-1,033.33	-283.33	-240.00
Shares Outstanding	24	24	20	36	36	36	36
Market Capitalization	199	120	112	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
L1 Capital Pty Ltd	10% Owner	Aug 03 '26	Sale	8.10	475,693	3,853,113	6,108,910	Aug 04
L1 Capital Pty Ltd	10% Owner	Jul 31 '26	Sale	8.15	48,711	396,995	6,584,603	Aug 04
L1 Capital Pty Ltd	10% Owner	Jul 30 '26	Sale	8.20	558,633	4,580,791	6,633,314	Jul 31
L1 Capital Pty Ltd	10% Owner	Jul 29 '26	Sale	8.04	155,505	1,250,260	7,191,947	Jul 31
L1 Capital Pty Ltd	10% Owner	Jul 28 '26	Sale	8.09	208,731	1,688,634	7,347,452	Jul 29
L1 Capital Pty Ltd	10% Owner	Jul 27 '26	Sale	6.78	281,161	1,906,771	5,359,470	Jul 29
L1 Capital Pty Ltd	10% Owner	Jul 24 '26	Sale	8.13	23,000	186,990	7,789,000	Jul 28
L1 Capital Pty Ltd	10% Owner	Jan 22 '26	Buy	5.75	10,000,000	57,500,000	13,219,814	Jul 28
L1 Capital Pty Ltd	10% Owner	Oct 28 '25	Buy	0.00	2,666,668	0	5,407,814	Jul 28
Moss Gregory S.	Director	Jun 07 '26	Option Exercise	0.00	17,580	0	17,580	Jun 09
Roberts David B	Director	Jun 07 '26	Option Exercise	0.00	17,580	0	17,580	Jun 09
McDonnell Matthew	Chief Financial Officer	Jun 05 '26	Option Exercise	6.27	62,001	388,885	62,001	Jun 09
Knight Susan Elizabeth	Director	Jun 02 '26	Buy	9.29	11,000	102,229	11,000	Jun 04
Seaberg John D	Director	Dec 16 '25	Option Exercise	0.00	27,777	0	43,635	Dec 18
St Denis David	Chief Operating Officer	Dec 16 '25	Option Exercise	0.00	166,666	0	166,666	Dec 18

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.